M Schneiderman1, N Czuzoj-Shulman2, A R Spence2, H A Abenhaim1,2. 1. Department of Obstetrics and Gynaecology, Jewish General Hospital, Montreal, QC, Canada. 2. Centre for Clinical Epidemiology and Community Studies, Jewish General Hospital, Montreal, QC, Canada.
Abstract
OBJECTIVE: To assess if pregnancies among women with Addison's disease (AD) are at higher risk of adverse maternal and neonatal outcomes. DESIGN: Population-based retrospective cohort study. SETTING/POPULATION: All births in the United States' Healthcare Cost and Utilization Project-Nationwide Inpatient Sample from 2003 to 2011. METHODS: Baseline characteristics were compared between women with AD and those without, and prevalence over time was measured. Logistic regression was used to estimate the effect of AD on maternal and neonatal outcomes by calculating the crude and adjusted odds ratios (OR) and corresponding 95% confidence intervals (95% CI). RESULTS: We calculated a prevalence of AD in pregnancy of 5.5/100 000, increasing from 5.6 to 9.6/100 000 (P = 0.0001) over the 9-year study period. Compared with women without AD, women with AD were more likely to deliver preterm (OR 1.50, 95% CI 1.16-1.95), deliver by caesarean section (OR 1.32, 95% CI 1.08-1.61), have impaired wound healing (OR 4.28, 95% CI 2.55-7.18), develop infections (OR 2.44, 95% CI 1.66-3.58) and develop thromboembolism (OR 5.21, 95% CI 2.15-12.63), require transfusions (OR 6.69, 95% CI 4.69-9.54), and have prolonged postpartum hospital admissions (OR 5.71, 95% CI 4.37-7.47). Maternal mortality was significantly higher than in the comparison group (OR 22.30, 95% CI 6.82-72.96). Congenital anomalies (OR 3.62, 95% CI 2.05-6.39) and small-for-gestational age infants (OR 1.78, 95% CI 1.15-2.75) were more likely in these pregnancies. CONCLUSIONS: Addison's disease significantly increases the risk of severe adverse maternal and neonatal outcomes, so pregnant women with AD are best managed in tertiary-care centres. TWEETABLE ABSTRACT: Pregnancies complicated by Addison's disease have an increased risk of adverse maternal and neonatal outcomes.
OBJECTIVE: To assess if pregnancies among women with Addison's disease (AD) are at higher risk of adverse maternal and neonatal outcomes. DESIGN: Population-based retrospective cohort study. SETTING/POPULATION: All births in the United States' Healthcare Cost and Utilization Project-Nationwide Inpatient Sample from 2003 to 2011. METHODS: Baseline characteristics were compared between women with AD and those without, and prevalence over time was measured. Logistic regression was used to estimate the effect of AD on maternal and neonatal outcomes by calculating the crude and adjusted odds ratios (OR) and corresponding 95% confidence intervals (95% CI). RESULTS: We calculated a prevalence of AD in pregnancy of 5.5/100 000, increasing from 5.6 to 9.6/100 000 (P = 0.0001) over the 9-year study period. Compared with women without AD, women with AD were more likely to deliver preterm (OR 1.50, 95% CI 1.16-1.95), deliver by caesarean section (OR 1.32, 95% CI 1.08-1.61), have impaired wound healing (OR 4.28, 95% CI 2.55-7.18), develop infections (OR 2.44, 95% CI 1.66-3.58) and develop thromboembolism (OR 5.21, 95% CI 2.15-12.63), require transfusions (OR 6.69, 95% CI 4.69-9.54), and have prolonged postpartum hospital admissions (OR 5.71, 95% CI 4.37-7.47). Maternal mortality was significantly higher than in the comparison group (OR 22.30, 95% CI 6.82-72.96). Congenital anomalies (OR 3.62, 95% CI 2.05-6.39) and small-for-gestational age infants (OR 1.78, 95% CI 1.15-2.75) were more likely in these pregnancies. CONCLUSIONS: Addison's disease significantly increases the risk of severe adverse maternal and neonatal outcomes, so pregnant women with AD are best managed in tertiary-care centres. TWEETABLE ABSTRACT: Pregnancies complicated by Addison's disease have an increased risk of adverse maternal and neonatal outcomes.
Authors: Christina Bothou; Gurpreet Anand; Dingfeng Li; Tina Kienitz; Khyatisha Seejore; Chiara Simeoli; Andreas Ebbehoj; Emma G Ward; Rosa Maria Paragliola; Rosario Ferrigno; Klaus Badenhoop; Sophie Bensing; Marianne Oksnes; Daniela Esposito; Ragnhildur Bergthorsdottir; William Drake; Jeanette Wahlberg; Nicole Reisch; Stefanie Hahner; Simon Pearce; Peter Trainer; Gwendolin Etzrodt-Walter; Sébastien P Thalmann; Åse B Sævik; Eystein Husebye; Andrea M Isidori; Henrik Falhammar; Gesine Meyer; Salvatore M Corsello; Rosario Pivonello; Robert Murray; Irina Bancos; Marcus Quinkler; Felix Beuschlein Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: P Naomi Franco; Lara M Durrant; Desirelys Carreon; Elizabeth Haddad; Adam Vergara; Catherine Cascavita; Andre Obenaus; William J Pearce Journal: Am J Physiol Regul Integr Comp Physiol Date: 2019-10-02 Impact factor: 3.619
Authors: Renata Świątkowska-Stodulska; Agata Berlińska; Katarzyna Stefańska; Maciej Zieliński; Sebastian Kwiatkowski; Joanna Połom; Elżbieta Andrysiak-Mamos; Piotr Wydra; Krzysztof Sworczak Journal: Front Immunol Date: 2022-06-29 Impact factor: 8.786
Authors: Barbara Gardella; Andrea Gritti; Annachiara Licia Scatigno; Anna Maria Clelia Gallotti; Francesca Perotti; Mattia Dominoni Journal: Front Med (Lausanne) Date: 2022-09-14